Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP) distribution and sales agreement in Israel with TrueMed Ltd. According to Race, TrueMed is a pharmaceutical distributor with experience in driving NPPs in Israel.…
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy Partners LLC (BioSynergy) to pursue licensing and other deals for Bisantrene (the ‘Agreement’). BioSynergy is a transaction consulting business owned by Dr John Cullity, a non-executive…
Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to assist Race with partnering and funding opportunities in the US, with a focus on Houston, Texas. Mr Lee is well-connected to the MD Anderson…
Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood Acute Myeloid Leukaemia (AML). The RPD designation means Bisantrene has…
The poster below details the long-term survival case report of two paediatric relapsed or refractory Acute Myeloid Leukemia patients treated with Bisantrene Combination Therapy.
Race Oncology is pleased to announce that approval has been received from the Medicines and Healthcare products Regulatory Agency (MHRA) for importation and distribution of Bisantrene as an unlicensed medicine in the UK. The letter from the MHRA was received…
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene to treat childhood relapsed/refractory AML (Acute Myeloid Leukaemia). The report will be published at a forthcoming oncology conference in France. The case report describes two…
Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and Schering-Plough in the US, and he has consulted to…
In a major development for the Australian biotech sector, ASX-listed oncology drug developer, Viralytics, has been sold to US-based big pharma, Merck, for US$502 million. As a former Director of Viralytics from 2008 – 2014, current Race Oncology Managing Director…
Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled, “Compositions to Improve the Therapeutic Benefit of Bisantrene and Analogs and…
